Emerging antiarrhythmic agents: a personal view from the Far East

Abstract

Introduction: Arrhythmia treatments today take three different approaches. One uses electronic devices, such as electronic pacemakers or defibrillators, and this is regarded as life-saving in cases of bradyarrhythmias and ventricular fibrillation. Another is the ablation technique which eliminates abnormal pacemakers and/or conductive pathways by applying thermal or cryo-injury to pathological portions of the heart. The most classical one is the antiarrhythmic drugs, but are they effective and safe?

Areas covered: Recent development of the understanding of arrhythmias, cardiac ionic channels and antiarrhythmic drugs covered by papers mostly published after 2000 are discussed.

Expert opinion: The market size of the antiarrhythmic drugs is small, but various multichannel acting drugs may become candidates as antiarrhythmic drugs. As the cardiac ionic channels have become recognized as proteins, the molecular target for antiarrhythmic drugs has become apparent, but at the same time accurate data on clinical effectiveness and safety are required for drug approval; thus, few atrium selective drugs, such as IKur, IKACh and IKAde blocking drugs and amiodarone-like multichannel acting drugs are being developed.

Keywords::

• amiodarone-like drugs
• atrial fibrillation
• IKACh
• IKAde
• IKur

Acknowledgement

The author thanks T Takenaka, Astellas Pharma, and K Ogino, Nihon Kohden, for supplying market data. The author also thanks BF Yang, Harbin Medical University, and NH Chen, Peking Union Medical College for giving Chinese drug information and Y Hashimoto for English language editing.